Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Topical Povidone-Iodine for Treatment of Giant Fornix Syndrome

Vahdani, Kaveh M.D., F.R.C.Ophth.; Rose, Geoffrey E. D.Sc., F.R.C.Ophth.

Ophthalmic Plastic & Reconstructive Surgery: September/October 2019 - Volume 35 - Issue 5 - p e114–e115
doi: 10.1097/IOP.0000000000001441
Case Reports

Over a 2-year period, a 68-year-old woman suffered multiple recurrences of left giant fornix syndrome during the repeated tailing of intensive topical steroids and antibiotics; she had also undergone surgery to reduce the left upper fornix. After a further recurrence during tailing of topical therapy for bilateral disease, treatment with 4 times daily preservative-free povidone-iodine 5% eyedrops was started—with a marked improvement of symptoms and signs within a week. The patient is maintained, symptom-free, on once-daily povidone-iodine drops and dexamethasone 0.1% drops. The dramatic improvement on topical povidone-iodine therapy might suggest that, as an initial therapy, this might be more effective than the previously-recommended regime of hourly potent topical steroids and antibiotics.

Preservative-free povidone-iodine 5% eyedrops rapidly controlled giant fornix syndrome in a patient who had multiple recurrences of the condition while tailing repeated courses of intensive topical steroids and antibiotics, and prior upper fornix-reduction surgery.

Adnexal Service, Moorfields Eye Hospital, City Road, London EC1V 2PD, United Kingdom

Accepted for publication June 27, 2019.

Supported by the National Institute of Health Research (NIHR) Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology (GER).

The authors have no financial or conflicts of interest to disclose.

Address correspondence and reprint requests to Geoffrey E. Rose, D.Sc., F.R.C.Ophth., Adnexal Service, Moorfields Eye Hospital NHS Foundation Trust, City Road. London EC1V 2PD, United Kingdom. E-mail:

© 2019 by The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc., All rights reserved.